Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation

Jiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently approved as an alternative to warfarin for pr...

Full description

Bibliographic Details
Main Authors: Choi JC, DiBonaventura Md, Kopenhafer L, Nelson WW
Format: Article
Language:English
Published: Dove Medical Press 2014-02-01
Series:Patient Preference and Adherence
Online Access:http://www.dovepress.com/survey-of-the-use-of-warfarin-and-the-newer-anticoagulant-dabigatran-i-a15740
_version_ 1818528380661792768
author Choi JC
DiBonaventura Md
Kopenhafer L
Nelson WW
author_facet Choi JC
DiBonaventura Md
Kopenhafer L
Nelson WW
author_sort Choi JC
collection DOAJ
description Jiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently approved as an alternative to warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran has a fixed dosage and few drug interactions, and does not require anticoagulation monitoring or dietary restrictions.Methods: This study aimed to describe and compare characteristics of patients with atrial fibrillation who used dabigatran or only warfarin. Patients with a self-reported diagnosis of atrial fibrillation aged ≥18 years who were receiving (or had received) warfarin or dabigatran completed an online survey. Differences in characteristics of dabigatran and warfarin users were tested using chi-squared tests and analysis of variance for categorical and continuous variables, respectively.Results: Overall, 364 patients were surveyed (204 warfarin users, 160 dabigatran users). The mean age was 65.1 years, and 68.7% were male. Dabigatran users were more likely than warfarin users to be female (36.9% versus 27.0%) and to have experienced adverse events, including gastrointestinal bleeding, in the 3 months before the survey (21.9% versus 6.9%; P<0.05). Both groups reported high medication adherence (dabigatran users 0.65 versus warfarin users 0.63 missed doses/month). Dabigatran users were more likely than warfarin users to discuss treatment options with their physician before beginning therapy (36.9% versus 24.5%; P<0.05) and less likely to switch anticoagulant medication (10.7% versus 31.9%; P<0.05). Although dabigatran users were more likely to experience adverse events, they reported greater satisfaction with anticoagulation treatment than warfarin users.Conclusion: The efficacy and convenience reported by dabigatran users resulted in greater treatment satisfaction among dabigatran users, even though adverse events decreased it. Treatment strategies that minimize adverse events may improve treatment satisfaction and adherence among patients with atrial fibrillation.Keywords: atrial fibrillation, warfarin, dabigatran
first_indexed 2024-12-11T06:49:02Z
format Article
id doaj.art-9e11177da4f34ae4a99795fe453e0fa4
institution Directory Open Access Journal
issn 1177-889X
language English
last_indexed 2024-12-11T06:49:02Z
publishDate 2014-02-01
publisher Dove Medical Press
record_format Article
series Patient Preference and Adherence
spelling doaj.art-9e11177da4f34ae4a99795fe453e0fa42022-12-22T01:16:59ZengDove Medical PressPatient Preference and Adherence1177-889X2014-02-012014default16717715740Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillationChoi JCDiBonaventura MdKopenhafer LNelson WWJiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently approved as an alternative to warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran has a fixed dosage and few drug interactions, and does not require anticoagulation monitoring or dietary restrictions.Methods: This study aimed to describe and compare characteristics of patients with atrial fibrillation who used dabigatran or only warfarin. Patients with a self-reported diagnosis of atrial fibrillation aged ≥18 years who were receiving (or had received) warfarin or dabigatran completed an online survey. Differences in characteristics of dabigatran and warfarin users were tested using chi-squared tests and analysis of variance for categorical and continuous variables, respectively.Results: Overall, 364 patients were surveyed (204 warfarin users, 160 dabigatran users). The mean age was 65.1 years, and 68.7% were male. Dabigatran users were more likely than warfarin users to be female (36.9% versus 27.0%) and to have experienced adverse events, including gastrointestinal bleeding, in the 3 months before the survey (21.9% versus 6.9%; P<0.05). Both groups reported high medication adherence (dabigatran users 0.65 versus warfarin users 0.63 missed doses/month). Dabigatran users were more likely than warfarin users to discuss treatment options with their physician before beginning therapy (36.9% versus 24.5%; P<0.05) and less likely to switch anticoagulant medication (10.7% versus 31.9%; P<0.05). Although dabigatran users were more likely to experience adverse events, they reported greater satisfaction with anticoagulation treatment than warfarin users.Conclusion: The efficacy and convenience reported by dabigatran users resulted in greater treatment satisfaction among dabigatran users, even though adverse events decreased it. Treatment strategies that minimize adverse events may improve treatment satisfaction and adherence among patients with atrial fibrillation.Keywords: atrial fibrillation, warfarin, dabigatranhttp://www.dovepress.com/survey-of-the-use-of-warfarin-and-the-newer-anticoagulant-dabigatran-i-a15740
spellingShingle Choi JC
DiBonaventura Md
Kopenhafer L
Nelson WW
Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
Patient Preference and Adherence
title Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
title_full Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
title_fullStr Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
title_full_unstemmed Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
title_short Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
title_sort survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
url http://www.dovepress.com/survey-of-the-use-of-warfarin-and-the-newer-anticoagulant-dabigatran-i-a15740
work_keys_str_mv AT choijc surveyoftheuseofwarfarinandtheneweranticoagulantdabigatraninpatientswithatrialfibrillation
AT dibonaventuramd surveyoftheuseofwarfarinandtheneweranticoagulantdabigatraninpatientswithatrialfibrillation
AT kopenhaferl surveyoftheuseofwarfarinandtheneweranticoagulantdabigatraninpatientswithatrialfibrillation
AT nelsonww surveyoftheuseofwarfarinandtheneweranticoagulantdabigatraninpatientswithatrialfibrillation